Phase 2Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)
- Sponsor
- Angitia Incorporated Limited (Industry)
- Enrolment
- 80 planned
- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- AGA2115; Placebo
- Ages
- adults, older adults
- Registry
- NCT07062588
Full record on ClinicalTrials.gov
From the registry
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
Primary outcomes
- Percent change from Baseline at Month 12 in lumbar spine BMD
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered